77 results on '"Del Conte A"'
Search Results
2. 266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)
3. LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
4. 272P Primary prevention of bone fractures in patients (pts) with hormone receptor (HR)+ early breast cancer (EBC) during adjuvant hormonal therapy (HT): The predict & prevent project (P&P)
5. 1785P Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study
6. 162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
7. P-249 Short-term results of surgery in elderly (>65 years) versus younger patients with Stage I-II colonic adenocarcinoma: a case-control study
8. 266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)
9. 412P Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
10. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer
11. LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
12. 1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI)
13. 412P Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
14. Nonmyeloablative conditioning for patients with hematological malignancies and solid tumors undergoing allogeneic stem cell transplantation (SCT)
15. 1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI)
16. Analysis of circulating biomarkers in a randomized phase II trial of maintenance oral metronomic vinorelbine in advanced NSCLC following platinum-based chemotherapy: A correlative MA.NI.LA. trial study
17. The GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors
18. Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial
19. Analysis of circulating biomarkers in a randomized phase II trial of maintenance oral metronomic vinorelbine in advanced NSCLC following platinum-based chemotherapy: A correlative MA.NI.LA. trial study
20. The GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors
21. Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial
22. Clinical features of never smoker patients with lung squamous cell carcinoma: a retrospective multicenter study
23. The close link between anxiety and cluster symptoms in lung cancer patients during first-line chemotherapy: further data from a dedicated WALCE (Women Against Lung Cancer in Europe) survey
24. Does second-line therapy affect the outcome of the patients with cholangiocarcinoma? A single institution experience
25. Predictive markers of survival in patients with pulmonary metastases and malignant pleural effusion
26. The close link between anxiety and cluster symptoms in lung cancer patients during first-line chemotherapy: further data from a dedicated WALCE (Women Against Lung Cancer in Europe) survey
27. Does second-line therapy affect the outcome of the patients with cholangiocarcinoma? A single institution experience
28. Relationship between overall survival and preoperative parameters in patients with colorectal cancer and synchronous liver and lung metastases
29. Analysis of factors affecting survival in patients with simultaneous liver and pulmonary metastases from colorectal cancer
30. Predictive markers of survival in patients with pulmonary metastases and malignant pleural effusion
31. Clinical features of never smoker patients with lung squamous cell carcinoma: A retrospective multicenter study
32. Relationship between overall survival and preoperative parameters in patients with colorectal cancer and synchronous liver and lung metastases
33. Analysis of factors affecting survival in patients with simultaneous liver and pulmonary metastases from colorectal cancer
34. 1510TiP - The GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors
35. 1404P - Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial
36. 139P - Analysis of circulating biomarkers in a randomized phase II trial of maintenance oral metronomic vinorelbine in advanced NSCLC following platinum-based chemotherapy: A correlative MA.NI.LA. trial study
37. Chemotherapy-induced nausea and vomiting (CINV) in patients with stage III/IV lung cancer during the first-line treatment: assessment by physician, nurse and patient. Preliminary results from an Italian multicenter survey
38. Maintenance Therapy (MT) for non-squamous advanced NSCLC: a multicenter Italian survey about patients (pts)' perspectives and physicians' awareness
39. Chemotherapy-induced nausea and vomiting (CINV) in patients with stage III/IV lung cancer during the first-line treatment: assessment by physician, nurse and patient. Preliminary results from an Italian multicenter survey
40. E18 - Clinical features of never smoker patients with lung squamous cell carcinoma: a retrospective multicenter study
41. E11 - The close link between anxiety and cluster symptoms in lung cancer patients during first-line chemotherapy: further data from a dedicated WALCE (Women Against Lung Cancer in Europe) survey
42. D29 - Does second-line therapy affect the outcome of the patients with cholangiocarcinoma? A single institution experience
43. P-176 Nabpaclitaxel plus gemcitabine as induction chemotherapy (CT) followed by chemoradiation (CRT) in locally advanced pancreatic cancer (LAPC)
44. Usefulness of Lung Palpation Through Thoracotomy for Metastasectomy in Patients with Non-Imaged Pulmonary Nodules
45. Factors Affecting Survival in Patients with Pulmonary Metastases from Colorectal Cancer with Previously Resected Liver Metastases Who Underwent Lung Metastasectomy
46. Tartrate-Resistant Acid Phosphatase Isoform 5B (TRACP 5B) As Serum Marker of Bone Metastases From Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer. Preliminary Results
47. Improved Quality of Life of Patients with Malignant Pleural Effusion Who Underwent Video-Assisted Minimally Invasive Thoracentesis and Talc Pleurodesis
48. Accuracy of Pleural Carcinoembryonic Antigen (CEA) Assay in Patients with Benign and Malignant Pleural Effusions Requiring Thoracentesis
49. 1373P - Clinical features of never smoker patients with lung squamous cell carcinoma: A retrospective multicenter study
50. 153P - Predictive markers of survival in patients with pulmonary metastases and malignant pleural effusion
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.